Skip to main content
Erschienen in: Investigational New Drugs 4/2012

01.08.2012 | PRECLINICAL STUDIES

Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer

verfasst von: Jinah Park, Eunju Park, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Woo-Ho Kim, Do-Youn Oh, Yung-Jue Bang

Erschienen in: Investigational New Drugs | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Summary

P-cadherin is frequently up-regulated in solid tumors such as gastric, colon, lung, pancreatic and breast cancers. Although P-cadherin promotes cadherin-mediated cell adhesion, the gastric cancer-linked regulation of P-cadherin has not been extensively investigated. In this study, we found epigenetic regulation of P-cadherin in human gastric cancer cells that was induced by treatment with DNA demethylating drug and histone deacetylase inhibitor. Silencing P-cadherin by using siRNA induces apoptosis in gastric cells and blocks expression of Tie-2, an angiogenic receptor tyrosine kinase. In contrast, ectopically expressed P-cadherin by generating P-cadherin stable cell line enhances Tie-2 expression and cell mobility. We also demonstrated that inhibition of P-cadherin by PF-03732010, a fully humanized anti-P-cadherin IgG1 monoclonal antibody, suppressed cell migration in vitro and tumor growth in BALB/c nude mice bearing SNU620 gastric cancer xenograft. The data reported here are the first to reveal that the inhibition of P-cadherin decreases tumor cell migration and blocks a tumorigenesis by down-regulation of Tie-2 in gastric cancer. This demonstrates the potential for P-cadherin to be used as a target for treatment of gastric cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ (2008) Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 9(3):279–287. doi:10.1016/S1470-2045(08)70072-X CrossRefPubMed Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ (2008) Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 9(3):279–287. doi:10.​1016/​S1470-2045(08)70072-X CrossRefPubMed
3.
Zurück zum Zitat Song SH, Jong HS, Choi HH, Inoue H, Tanabe T, Kim NK, Bang YJ (2001) Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5′ CpG island in human gastric carcinoma cells. Cancer Res 61(11):4628–4635PubMed Song SH, Jong HS, Choi HH, Inoue H, Tanabe T, Kim NK, Bang YJ (2001) Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5′ CpG island in human gastric carcinoma cells. Cancer Res 61(11):4628–4635PubMed
5.
Zurück zum Zitat Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y (2008) Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 14(20):6487–6495CrossRefPubMed Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y (2008) Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 14(20):6487–6495CrossRefPubMed
6.
Zurück zum Zitat Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC (2007) P-cadherin expression in breast cancer: a review. Breast Cancer Res 9(5):214CrossRefPubMed Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC (2007) P-cadherin expression in breast cancer: a review. Breast Cancer Res 9(5):214CrossRefPubMed
8.
Zurück zum Zitat Milicic A, Harrison LA, Goodlad RA, Hardy RG, Nicholson AM, Presz M, Sieber O, Santander S, Pringle JH, Mandir N, East P, Obszynska J, Sanders S, Piazuelo E, Shaw J, Harrison R, Tomlinson IP, McDonald SA, Wright NA, Jankowski JA (2008) Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res 68(19):7760–7768. doi:10.1158/0008-5472.CAN-08-0020 CrossRefPubMed Milicic A, Harrison LA, Goodlad RA, Hardy RG, Nicholson AM, Presz M, Sieber O, Santander S, Pringle JH, Mandir N, East P, Obszynska J, Sanders S, Piazuelo E, Shaw J, Harrison R, Tomlinson IP, McDonald SA, Wright NA, Jankowski JA (2008) Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res 68(19):7760–7768. doi:10.​1158/​0008-5472.​CAN-08-0020 CrossRefPubMed
9.
Zurück zum Zitat Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC (2005) P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11(16):5869–5877. doi:10.1158/1078-0432.CCR-05-0059 CrossRefPubMed Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC (2005) P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11(16):5869–5877. doi:10.​1158/​1078-0432.​CCR-05-0059 CrossRefPubMed
10.
Zurück zum Zitat Hibi K, Kitamura YH, Mizukami H, Goto T, Sakuraba K, Sakata M, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y (2009) Frequent CDH3 demethylation in advanced gastric carcinoma. Anticancer Res 29(10):3945–3947PubMed Hibi K, Kitamura YH, Mizukami H, Goto T, Sakuraba K, Sakata M, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y (2009) Frequent CDH3 demethylation in advanced gastric carcinoma. Anticancer Res 29(10):3945–3947PubMed
11.
Zurück zum Zitat Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y (2005) Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res 65(8):3092–3099. doi:10.1158/0008.5472.CAN-04-3646 PubMed Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y (2005) Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res 65(8):3092–3099. doi:10.​1158/​0008.​5472.​CAN-04-3646 PubMed
13.
Zurück zum Zitat Ronaghi M, Uhlen M, Nyren P (1998) A sequencing method based on real-time pyrophosphate. Science 281(5375):363–365CrossRefPubMed Ronaghi M, Uhlen M, Nyren P (1998) A sequencing method based on real-time pyrophosphate. Science 281(5375):363–365CrossRefPubMed
14.
Zurück zum Zitat Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynow E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender SL, Anderes K, Christensen JG, Vanarsdale T (2010) PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clin Cancer Res. doi:10.1158/1078-0432.CCR-10-1343 Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynow E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender SL, Anderes K, Christensen JG, Vanarsdale T (2010) PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clin Cancer Res. doi:10.​1158/​1078-0432.​CCR-10-1343
16.
Zurück zum Zitat Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X CrossRefPubMed Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697. doi:10.​1016/​S0140-6736(10)61121-X CrossRefPubMed
17.
Zurück zum Zitat Kim TY, Bang YJ, Robertson KD (2006) Histone deacetylase inhibitors for cancer therapy. Epigenetics 1(1):14–23CrossRefPubMed Kim TY, Bang YJ, Robertson KD (2006) Histone deacetylase inhibitors for cancer therapy. Epigenetics 1(1):14–23CrossRefPubMed
19.
Zurück zum Zitat Kwon O, Jeong SJ, Kim SO, He L, Lee HG, Jang KL, Osada H, Jung M, Kim BY, Ahn JS (2010) Modulation of E-cadherin expression by K-Ras; involvement of DNA methyltransferase-3b. Carcinogenesis 31(7):1194–1201. doi:10.1093/carcin/bgq071 CrossRefPubMed Kwon O, Jeong SJ, Kim SO, He L, Lee HG, Jang KL, Osada H, Jung M, Kim BY, Ahn JS (2010) Modulation of E-cadherin expression by K-Ras; involvement of DNA methyltransferase-3b. Carcinogenesis 31(7):1194–1201. doi:10.​1093/​carcin/​bgq071 CrossRefPubMed
20.
Zurück zum Zitat Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J (2009) A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15(6):489–500. doi:10.1016/j.ccr.2009.03.022 CrossRefPubMed Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J (2009) A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15(6):489–500. doi:10.​1016/​j.​ccr.​2009.​03.​022 CrossRefPubMed
23.
Zurück zum Zitat Martin V, Liu D, Fueyo J, Gomez-Manzano C (2008) Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol 23(6):773–780PubMed Martin V, Liu D, Fueyo J, Gomez-Manzano C (2008) Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol 23(6):773–780PubMed
24.
Zurück zum Zitat Nakayama T, Yoshizaki A, Kawahara N, Ohtsuru A, Wen CY, Fukuda E, Nakashima M, Sekine I (2004) Expression of Tie-1 and 2 receptors, and angiopoietin-1, 2 and 4 in gastric carcinoma; immunohistochemical analyses and correlation with clinicopathological factors. Histopathology 44(3):232–239CrossRefPubMed Nakayama T, Yoshizaki A, Kawahara N, Ohtsuru A, Wen CY, Fukuda E, Nakashima M, Sekine I (2004) Expression of Tie-1 and 2 receptors, and angiopoietin-1, 2 and 4 in gastric carcinoma; immunohistochemical analyses and correlation with clinicopathological factors. Histopathology 44(3):232–239CrossRefPubMed
25.
Zurück zum Zitat Martin V, Xu J, Pabbisetty SK, Alonso MM, Liu D, Lee OH, Gumin J, Bhat KP, Colman H, Lang FF, Fueyo J, Gomez-Manzano C (2009) Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene 28(24):2358–2363. doi:10.1038/onc.2009.103 CrossRefPubMed Martin V, Xu J, Pabbisetty SK, Alonso MM, Liu D, Lee OH, Gumin J, Bhat KP, Colman H, Lang FF, Fueyo J, Gomez-Manzano C (2009) Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene 28(24):2358–2363. doi:10.​1038/​onc.​2009.​103 CrossRefPubMed
Metadaten
Titel
Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer
verfasst von
Jinah Park
Eunju Park
Sae-Won Han
Seock-Ah Im
Tae-You Kim
Woo-Ho Kim
Do-Youn Oh
Yung-Jue Bang
Publikationsdatum
01.08.2012
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 4/2012
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-011-9710-9

Weitere Artikel der Ausgabe 4/2012

Investigational New Drugs 4/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.